GO
Loading...

Biogen Idec Inc

More

  • *Apple rallies after results, boosting tech names. NEW YORK, July 23- U.S. stocks were largely higher on Wednesday, with the S&P 500 hitting another record high after bullish results from tech giants Apple and Microsoft, though technical resistance and conflicts in Ukraine and the Gaza Strip kept gains in check.

  • *Microsoft sees end to Nokia losses, shares rise. NEW YORK, July 23- The S&P 500 hit a record high on Wednesday, lifted by bullish earnings from companies like Apple and Microsoft, though technical resistance and conflicts in Ukraine and the Gaza Strip kept gains in check.

  • As S&P nears 2,000, traders say keep an eye on this Wednesday, 23 Jul 2014 | 9:48 AM ET
    Traders work the floor of the New York Stock Exchange.

    Shaking off geopolitical flare-ups for now, analysts say the S&P 500 is taking aim at the 2,000 level, and the next round of earnings news could help.

  • *Microsoft sees end to Nokia losses, shares rise. NEW YORK, July 23- U.S. stocks were set to rise slightly at the open on Wednesday, boosted by bullish earnings from companies like Boeing, Pepsi and Microsoft, though conflicts in Ukraine and the Gaza Strip weighed on investor confidence.

  • *Microsoft sees end to Nokia losses, shares rise. NEW YORK, July 23- U.S. stock index futures edged up on Wednesday, boosted by bullish earnings from companies like Microsoft and Boeing, though conflicts in Ukraine and the Gaza Strip weighed on investor confidence.

  • Early movers: AAPL, MSFT, BA, DAL, DOW, PEP & more Wednesday, 23 Jul 2014 | 7:57 AM ET

    Some of the names on the move ahead of the open.

  • July 23- Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera treatment for multiple sclerosis, and the company raised its full-year profit forecast. U.S. sales of $585 million blew past Wall Street expectations in the $485 million range.

  • Biogen revenue trounces forecast as MS drug sales surge Wednesday, 23 Jul 2014 | 7:04 AM ET

    July 23- Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera oral treatment for multiple sclerosis, and the company raised its full-year profit forecast. The company on Wednesday said it had earned $723.1 million, or $3.01 per share, in the second quarter.

  • Politics fade as earnings take over Friday, 18 Jul 2014 | 6:30 PM ET
    Espirito Santo International is the parent company of several institutions, including Banco Espirito Santo.

    Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.

  • UPDATE 2-Gambro acquisition boosts Baxter's sales Thursday, 17 Jul 2014 | 1:30 PM ET

    July 17- Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly adjusted earnings, driven primarily by a surge in sales of the dialysis products it gained from its acquisition of Gambro AB last year.

  • The Alzheimer's epidemic: Where we stand Friday, 11 Jul 2014 | 11:45 AM ET

    Although treatments for Alzheimer's have struggled, drugmakers are still working in the space, with 67 medicines currently in development.

  • Cramer: 4 strong stocks for months to come Wednesday, 9 Jul 2014 | 6:29 PM ET

    If the charts are to be believed, the path of least resistance for these 4 stocks should be higher.

  • Cramer: Six buyable themes in second half Tuesday, 1 Jul 2014 | 6:08 PM ET
    Jim Cramer on Mad Money.

    Cramer says the price action in Tuesday’s market is sending an important message about what to buy in the days ahead.

  • Dow's 7 underperformers—time to buy? Tuesday, 24 Jun 2014 | 8:52 AM ET
    Nike sneakers sit on display at a Foot Locker store inside the South Park Mall in Strongsville, Ohio, March 4, 2014.

    Of the 30 stocks on the Dow, only seven have not hit 52-week highs this year. Is it time to bet on these underperformers?

  • Aging stinks, so at least make some money from it Monday, 23 Jun 2014 | 8:00 AM ET

    The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.

  • *Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.

  • Shire braces for takeover bids, hires Citi: Sources Monday, 16 Jun 2014 | 2:25 PM ET
    Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc.

    Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.

  • Midday movers: Medtronic, Netflix, Tesla Motors & More Monday, 16 Jun 2014 | 12:12 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • June 16- A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.

  • WASHINGTON, June 6- The U.S. Food and Drug Administration said on Friday it approved Biogen Idec Inc's long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders. The FDA's ruling followed its approval in March of Biogen's hemophilia B treatment, Alprolix.